Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Compugen
Biotech
BMS oncology head swings to Syndax—Chutes & Ladders
BMS oncology head swings to Syndax. Stylus unsheathes with Bayer vet at helm. T1D Fund picks up former BMS dealmaker.
Darren Incorvaia
,
Zoey Becker
May 16, 2025 8:30am
Exscientia fires CEO—Chutes & Ladders
Feb 16, 2024 9:30am
Gilead downloads Compugen solid tumor program for $60M upfront
Dec 19, 2023 7:10am
FibroGen taps 2nd CSO in 10 months, snagging ex-Compugen exec
Jul 12, 2021 10:50am
Compugen's checkpoint inhibitor keeps cancer in check
Apr 27, 2020 7:00am
AACR: A look at next-gen CAR-T therapies for blood cancers
Apr 27, 2020 12:01am
